Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095973 | 0.92 | KMT2A (0.64) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL15095988 | 0.88 | KMT2A (0.76) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL189834 | 0.87 | KMT2A (0.52) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL4458442 | 0.86 | KMT2A (0.54) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL189805 | 0.85 | KMT2A (0.84) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL189003 | 0.82 | KMT2A (0.64) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL189589 | 0.80 | KMT2A (1.00) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL189314 | 0.78 | KMT2A (0.60) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL250848 | 0.74 | MAPT (0.53) | KMT2AL3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL189587 | 0.73 | KMT2A (0.56) | KMT2AL3MBTL1KDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | KMT2A 2013/4885L3MBTL1 3160/4885KDM4E 1964/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KMT2A 1063/4885L3MBTL1 2835/4885KDM4E 761/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | KMT2A 1079/4885L3MBTL1 2554/4885KDM4E 835/4885 |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | ERBB2, EGFR, ERBB3 | KMT2A 830/4885L3MBTL1 4649/4885KDM4E 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.